Parabolic Drugs Limited reported audited standalone earnings results for the fourth quarter and audited standalone and consolidated earnings results for the year ended March 31, 2018. For the quarter, on standalone basis, the company reported total revenue from operations (net) of INR 162.3 million compared to INR 220.9 million a year ago. Loss before exceptional items and extraordinary items and taxes was INR 138.0 million compared to profit of INR 584.3 million a year ago. Loss before extraordinary items and tax was INR 138.0 million compared to profit of INR 584.3 million a year ago. Net loss after taxation from continuing operations was INR 142.7 million or INR 2.37 per basic and diluted share compared to net profit of INR 577.0 million or INR 9.33 per basic and diluted share a year ago. For the year, on standalone basis, the company reported total revenue from operations (net) of INR 726.0 million compared to INR 737.2 million a year ago. Loss before exceptional items and extraordinary items and taxes was INR 548.2 million compared to loss of INR 1,052.3 million a year ago. Loss before extraordinary items and tax was INR 548.2 million compared to loss of INR 1,052.3 million a year ago. Net loss after taxation from continuing operations was INR 565.8 million or INR 9.21 per basic and diluted share compared to net loss of INR 1,082.8 million or INR 17.46 per basic and diluted share a year ago. For the year, on consolidated basis, the company reported total revenue from operations (net) of INR 731.6 million compared to INR 749.0 million a year ago. Loss before exceptional items and extraordinary items and taxes was INR 553.7 million compared to loss of INR 1,050.3 million a year ago. Loss before extraordinary items and tax was INR 553.7 million compared to loss of INR 1,050.3 million a year ago. Net loss after taxation from continuing operations was INR 571.3 million or INR 9.30 per basic and diluted share compared to net loss of INR 1,080.9 million or INR 17.46 per basic and diluted share a year ago.